CollPlant Biotechnologies’ (CLGN) Buy Rating Reiterated at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $14.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 270.47% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Price Performance

Shares of CLGN stock opened at $3.78 on Tuesday. The firm’s 50-day moving average is $3.92 and its two-hundred day moving average is $4.34. CollPlant Biotechnologies has a 12 month low of $3.24 and a 12 month high of $6.75. The company has a market capitalization of $43.27 million, a PE ratio of -2.45 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same period in the previous year, the business earned ($0.38) earnings per share. Sell-side analysts forecast that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Trading of CollPlant Biotechnologies

An institutional investor recently bought a new position in CollPlant Biotechnologies stock. Benjamin Edwards Inc. acquired a new stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned 0.21% of CollPlant Biotechnologies at the end of the most recent quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.